Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18363
Title: Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Authors: Gleeson, Mary;Peckitt, Clare;Cunningham, David;Gibb, Adam;Hawkes, Eliza A;Back, Morgan;Yasar, Binnaz;Foley, Kate;Lee, Rebecca;Dash, Joanna;Johnson, Hannah;O'Hara, Catherine;Wotherspoon, Andrew;Attygalle, Ayoma;Menasce, Lia;Shenjere, Patrick;Potter, Mike;Ethell, Mark E;Dearden, Claire;Radford, John;Chau, Ian;Linton, Kim
Affiliation: The Royal Marsden Hospital, London and Surrey , UK
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Department of Oncology, Austin Health, Heidelberg, Victoria, Australia
Eastern Health, Melbourne, Australia
The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Issue Date: Jul-2018
EDate: 2017-11-09
Citation: Leukemia & lymphoma 2018; 59(7): 1586-1595
Abstract: We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18363
DOI: 10.1080/10428194.2017.1393671
PubMed URL: 29119842
Type: Journal Article
Subjects: Peripheral T-cell lymphoma
chemotherapy
hematopoietic progenitor cell transplant
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.